Celera Genomics Group-an Applera Corp. Business and Laboratory Corporation of America Holdings Announce Licensing Agreement to Commercialize Breast Cancer Testing Assays

ROCKVILLE, Md. & BURLINGTON, N.C.--(BUSINESS WIRE)--Celera (NYSE:CRA), an Applera Corporation business, and Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH), a national leader in esoteric and oncology testing, today announced that they have signed an agreement granting LabCorp a license to Celera’s breast cancer metastasis and estrogen/progesterone receptor discoveries. The license agreement allows LabCorp to select from among Celera’s genomic findings to develop and commercialize two molecular oncology laboratory service tests. LabCorp plans to offer one test to help predict the risk of metastasis in early stage breast cancer patients, and a second test to provide a molecular assessment of hormonal receptor status, which is used to select women for endocrine therapy.